1525 results about "Thelial cell" patented technology

The invention belongs to the technical field of biology, and discloses a reagent combination or kit for constructing intestinal organs and application of the reagent combination or kit. According to the reagent combination or the kit, intestinal organs can be obtained from cell-derived epithelial cells obtained from a donor in a non-invasive manner, and the obtained intestinal organs can be cryopreserved and recovered and can be amplified in vitro for a long time; transcriptome characteristics are similar to those of real human small intestine tissues, and typical marker genes of various small intestine pedigree cell types are highly expressed; compared with intestinal organs obtained through induction of pluripotent stem cells, the intestinal organs have more intestinal pedigree characteristics, and the intestinal function development is more mature; after being promoted to be mature, the intestinal organ also highly expresses genes related to drug absorption and metabolism, has drug absorption capability similar to that of an immortalized intestinal cell line, but more prominently shows intestinal cell lineage characteristics, is closer to an intestinal environment in a real human body, and can be used for screening intestinal disease drugs; the intestinal barrier function is realized.

The invention relates to recombinant III-type humanized collagen and application of a composition containing the same to eyes. The invention provides an application of recombinant III type humanized collagen in preparation of a product for preventing and / or treating eye inflammation, a composition containing the recombinant III type humanized collagen, and an application of the composition in preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant III-type humanized collagen and the composition containing the recombinant III-type humanized collagen can obviously promote updating and repairing of corneal epithelial cells, and meanwhile, can inhibit release of inflammatory mediators, enhance eye tissue barriers, enhance tear film stability and relieve eye inflammation and eye dryness.

The invention discloses a 3D intestinal organ differentiation method based on human pluripotent stem cells and an induction culture medium and application thereof, and relates to the technical field of stem cells. According to a culture medium formula combination, intestinal organs can be differentiated into various cell types such as epithelial cells, neuroendocrine cells and endothelial cells; the method is a key mark for successful differentiation and functional maturation of intestinal organs. According to the 3D intestinal organ differentiation method disclosed by the invention, histological structures such as intestinal crypts are differentiated from intestinal organs generated by differentiation, and the intestinal organs can creep in a maintenance stage, so that the intestinal organs are changed from structural bionics to functional simulation, and the significance of the 3D intestinal organ differentiation method is far better than that of pure morphological simulation. Through a systematic culture medium formula, a clear operation process and a multi-stage induction strategy, the 3D intestinal organ with structural integrity, cell diversity and functional activity is successfully constructed, and the system provides an efficient, reliable and extensible in-vitro model platform for intestinal biological research and related application.

The invention provides a homogeneous electrochemical analysis method for exosome detection based on DNA-Pb < 2 + > functional nano-hydrogel and application, and relates to the technical field of biomedical diagnostic analysis method.The homogeneous electrochemical analysis method is constructed based on DNA nano-hydrogel prepared through a rolling circle amplification (RCA) method by combining a G-quadruplex structure and a Pb < 2 + > specific recognition mechanism; an epithelial cell adhesion molecule (EpCAM) on the surface of the exosome is selected as a detection target, the DNA nano-hydrogel is triggered to disintegrate by utilizing specific binding between the EpCAM and an aptamer thereof, then a large number of G-quadruplex structures generated by RCA are exposed, the G-quadruplex structures can be selectively bound with Pb < 2 + > and regulate and control electrochemical signal output, and the detection sensitivity is high. According to the method, a one-pot method, a rapid and efficient detection process is realized, and the whole process is completed within 45 minutes.

The invention belongs to the technical field of medical image detection, and particularly relates to an esophageal flora image intelligent detection method for risk prediction of gastroesophageal reflux disease, which comprises the following steps: acquiring flora images and clinical data, and constructing a perception network; quantifying flora displacement characteristics by using image registration; the method comprises the following steps of: extracting flora density, aggregation degree and fluorescence gradient characteristics by combining improved U-Net + + segmentation, fusing flora and epithelial cell lesion characteristics through space-time attention, generating a flora-host association map, constructing a flora dynamic evolution model by utilizing a space-time map convolutional network, predicting Barrett esophageal occurrence probability and flora diffusion trend, and predicting the occurrence probability of the Barrett esophagus. Calculating a lesion risk level through a flora imbalance quantification algorithm; in combination with reflux frequency and pH fluctuation, a flora-environment interaction model is used for simulating a field planting coefficient and correcting parameters, the parameters are transmitted to a diagnosis platform to deduce canceration risks, grading suggestions are triggered, and a visual report is generated. Therefore, the problems of long detection period, weak microscopic analysis capability and the like in the prior art are solved.

The invention relates to the technical field of image recognition, in particular to an adhesion focus positioning method for an endometriosis rat model, which comprises the following steps of: firstly, adjusting a clustering distance according to color difference between saturation connected domains and a position inertial system, and clustering to obtain a connected domain cluster; due to the fact that the connected domain clusters contain the ectopic glands, the clusters need to be screened to obtain the ectopic glands, the gland probability of each connected domain cluster is obtained according to the characteristic that columnar epithelial cells are distributed on the inner walls of the ectopic glands, and the possibility that each connected domain cluster belongs to the ectopic glands is judged; due to the fact that the ectopic glands are distributed in a concentrated mode, the abnormal probability of the connected domain clusters is obtained through the aggregation of the connected domain clusters with the high gland probability, the possibility that the connected domain clusters belong to the abnormal ectopic glands is further judged, and the focus positioning accuracy of the endometriosis rat model is higher.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The invention provides a methacrylic anhydride modified sclera extracellular matrix repair material and a curing method thereof, and belongs to the technical field of medical repair materials. The methacrylic anhydride modified sclera extracellular matrix repair material provided by the invention is prepared from the following raw materials: a methacrylic anhydride modified sclera extracellular matrix, methacrylated gelatin, a photoinitiator and a solvent. The sclera extracellular matrix modified by methacrylic anhydride is adopted, methacrylic anhydride contains methacrylic acid, double bonds can be introduced, the sclera extracellular matrix has the photo-initiation polymerization capacity, and in-situ gelling can be carried out at sclera and cornea damage positions under the action of a photoinitiator; the sclera extracellular matrix has good biocompatibility and histocompatibility, so that sclera matrix cells and corneal epithelial cells are adhered and proliferated, and the sutureless repair is realized; the methacrylated gelatin can provide a photo-crosslinking gelatin network under the action of a photoinitiator, so that cell adhesion and proliferation can be promoted, and repair is realized.

The invention discloses application of tannic acid combined triazole medicines in preparation of medicines for treating diseases caused by fungi, and belongs to the technical field of antifungal. A series of drug sensitive tests show that tannic acid lower than 3 [mu] g / ml has no influence on the activity of human vaginal epithelial cells, and after the tannic acid is combined with fluconazole, the tannic acid can significantly inhibit the growth activity of drug-resistant candida (including drug-resistant candida albicans and drug-resistant candida glabrata). In view of the natural property, wide source and low toxicity of tannic acid, the invention provides a new antifungal treatment strategy, and the tannic acid has important clinical application value for treating infection (such as vaginal candidiasis) caused by drug-resistant fungi, especially under the condition that the existing antifungal drugs are poor in effect. Therefore, the tannic acid combined triazole medicine can be used for preparing the medicine for treating diseases caused by fungi.

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.

The invention discloses a mucosal epithelial cell targeted oral ROS response type nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The oral ROS response type nano-enzyme comprises Ce-CDs carbon dots and a betaine polymer, and the betaine polymer is coated on the surfaces of the Ce-CDs carbon dots to form nano-particles; the Ce-CCDs carbon dots are prepared by taking a metal cerium source and chlorogenic acid as raw materials through a pyrolysis method. Through structural innovation and function integration, the prepared nano-enzyme shows outstanding advantages in the aspects of catalytic activity, targeted delivery, collaborative treatment, industrial application and the like, a new technical scheme is provided for efficient and safe treatment of inflammatory bowel diseases, and the nano-enzyme has remarkable technical innovation and clinical application value.

The invention belongs to the field of biological medicine, and particularly relates to an antibacterial peptide for inhibiting staphylococcus aureus and pseudomonas aeruginosa and application of the antibacterial peptide. The antibacterial peptide CAMP648NC is a novel cationic antibacterial peptide, the minimum inhibitory concentrations of the antibacterial peptide CAMP648NC to pathogenic bacteria staphylococcus aureus and pseudomonas aeruginosa are 16 [mu] g / mL and 32 [mu] g / mL respectively, the antibacterial peptide CAMP648NC has extremely low cytotoxicity, and after human skin keratinocytes HaCat and bronchial epithelial cells BEAS-2B are treated by the antibacterial peptide CAMP648NC with the concentration of 128 [mu] g / mL for 24 hours, the survival rates of 110.4% and 87.3% are still kept. Due to the characteristics, the compound shows extremely high medical drug antibacterial value, and alternative medicinal resources are provided for clinically resisting the two human pathogenic bacteria in the future.

The invention discloses an anti-neurodegeneration exosome composition as well as a preparation method and application thereof. The anti-neurodegeneration exosome composition is prepared from the following components in parts by mass: 5 to 25 parts of human exfoliated deciduous tooth stem cell exosome, 25 to 85 parts of plant-derived exosome-like nano-vesicles, 12 to 10 parts of ginsenoside Rg, 2 to 10 parts of curcumin and 10 to 20 parts of auxiliary materials. The anti-neurodegeneration exosome composition contains a large amount of cell factors, growth factors, miRNA, mRNAs and other components, is easy to fuse with cell membranes of intestinal epithelial cells, can selectively deliver bioactive substances to recipient cells through a blood-brain barrier, carries out information transmission among different cells, regulates signal transduction among the cells, and has a good anti-neurodegeneration effect. The effects of resisting oxidation, resisting inflammation, resisting aging and the like are achieved.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.

The invention discloses a ferroptosis inhibitor and application of the ferroptosis inhibitor in radiation pneumonitis drugs, and relates to the technical field of biological medicines. The specific preparation method comprises the following steps: adding the ferroptosis inhibitor and the auxiliary agent into the solvent, and dissolving to obtain the ferroptosis inhibitor composition; wherein the ferroptosis inhibitor is isoorientin; the auxiliary agent is a glucosamine derivative; the solvent is a serum-free DMEM culture medium. The ferroptosis inhibitor composition prepared by the method provided by the invention can effectively reduce the rise of active oxygen, ferrous ions and malondialdehyde levels of human pulmonary epithelial cells BEAS-2b and mouse pulmonary epithelial cells MLE-12 caused by irradiation, restore cell mitochondrial membrane potential enrichment and inhibit the expression of various inflammatory factors in irradiated cells; therefore, the process of radiation pneumonitis is remarkably improved, and a new medication strategy is provided for research on radiation pneumonitis drugs.

The invention relates to the technical field of cell engineering, and particularly discloses a construction method and application of a sika deer immortalized renal epithelial cell line, and the construction method comprises the following steps: taking renal epithelial primary cells from healthy sika deer renal cortex tissues to obtain primary renal epithelial cells; treating the primary renal epithelial cells with trypsin to obtain a cell suspension; inoculating the cell suspension into a complete culture medium, and transfecting with lentivirus loaded with SV40 large T antigen genes to obtain transfected cells; 3 [mu] g / mL puromycin is applied to the transfected cells for selective culture, so that non-transfected cells are eliminated, and drug-resistant cells are obtained; carrying out continuous passage on the drug-resistant cells for at least 30 generations to obtain the immortalized renal epithelial cell line of the sika deer; according to the invention, through a specific action mechanism (inhibiting a p53 / pRb pathway and blocking cell cycle exit) of the SV40 large T antigen, a proliferation limit caused by inhibition of telomerase activity of primary cells of the cervidae animals is overcome, and a cell resource library capable of realizing continuous passage is established.

The present invention relates to an exogenous target gene expression cassette for delivering an exogenous target gene to the retina, in particular AIPL1 to retinal pigment epithelial cells and photoreceptor cells, comprising an IRBP enhancer sequence, a rhodopsin kinase (RK) promoter sequence and a CAG intron sequence, which are operatively linked, and an exogenous target gene. The present invention also relates to a recombinant adeno-associated viral vector comprising a viral capsid comprising a capsid protein or a capsid protein variant and a viral vector genome comprising an expression cassette encoding for specifically expressing an exogenous target gene in retinal pigment epithelial cells and photoreceptor cells. The recombinant adeno-associated virus vector can be used for relieving or treating retinal degenerative eye diseases by intravitreal administration or subretinal administration.

The invention discloses a method for establishing an animal model for age-related retinopathy caused by lipid metabolism disorder, and the animal model is obtained by specifically knocking out Lss genes from mouse retinal pigment epithelium (RPE) cells by means of a CRISPR / Cas9 gene editing technology. The age-related retinopathy model mouse constructed by the invention shows a retinopathy phenotype with retinal lipid deposition and reduced visual function at the age of 5 months, and the retinopathy is further aggravated along with the increase of the age of the mouse and is similar to the phenotype of age-related retinopathy related to lipid metabolism disorder clinically; and an ideal and effective animal model is provided for researching age-related retinopathy.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention provides an application of a lactobacillus paracasei IOB413 metagen in prevention of helicobacter pylori infection, and relates to the technical field of microorganisms. The lactobacillus paracasei IOB413 metaplasm can competitively occupy gastric epithelial cell adhesion sites to directly block the initial colonization of helicobacter pylori, so that infection preposed interception is realized, and the lactobacillus paracasei IOB413 metaplasm is suitable for early prevention of high-incidence people. The compound has dual mechanisms of site blocking and urease inhibition, and can cooperate with antibiotics to improve the eradication rate and reduce the drug resistance. Animal experiments show that the traditional Chinese medicine composition can reduce gastric mucosa proinflammatory factors in a dose-dependent manner, improve the activity of antioxidant enzymes, reduce lipid peroxidation products, relieve mucosa lesion, promote repair and reduce the risk of complications; moreover, gastrointestinal hormone disorder can be reversed, the digestive function is maintained, and related discomfort is relieved.

The invention relates to the technical field of medicine screening, in particular to an active substance screening platform and application thereof. The active substance screening platform comprises a cell combination; the cell combination comprises immunoregulation screening cells and antioxidant screening cells; the immunoregulation screening cell is a mouse mononuclear macrophage RAW 264.7 carrying an NF-kappa B element conserved sequence and a reporter gene; the antioxidant screening cell is a porcine small intestine epithelial cell IPEC-J2 cell carrying an ARE element conserved sequence and a reporter gene. The invention provides a screening platform based on a specific cell combination, which can quickly obtain an active substance with immune regulation, antioxidation or two functions from a large number of candidate active substances, has the advantages of low cost and high efficiency, and has important application value.

The invention belongs to the field of pharmacy, and relates to a medicine for treating pulmonary fibrosis, in particular to application of an anti-Gremlin1 antibody to preparation of a medicine for preventing and treating pulmonary fibrosis. The Gremlin1 antibody disclosed by the invention can be applied to prevention and treatment of pulmonary fibrosis, effectively improves bleomycin (BLM)-induced pulmonary fibrosis lesions of mice and improves the survival rate of the mice. Compared with a BLM group, the mouse inspiration capacity (IC) and the lung static compliance (CRS) treated by the Gremlin1 antibody are remarkably improved, the hydroxyproline content in lung tissue is remarkably reduced, and compared with the BLM group, the Ashcroft score, the collagen deposition area in Masson three-color dyeing and the Sirius red dyeing area of an antibody intervention group are remarkably reduced, and the proportion of activated endothelial cells and the proportion of transition-state epithelial cells are remarkably reduced. Therefore, the Gremlin1 antibody can be used for preparing the medicine for preventing and / or treating the pulmonary fibrosis.

This invention discloses a strain of *Lactobacillus plantarum* Grx402 with the ability to promote intestinal absorption of short-chain fatty acids. *Lactobacillus plantarum* Grx402 was isolated from the intestines of long-lived individuals in Bama, Guangxi (CGMCC No. 28585). Using a Caco-2 cell model to construct an intestinal absorption model of short-chain fatty acids (SCFAs), it was found that *Lactobacillus plantarum* Grx402 can promote the absorption and transport of acetic acid, propionic acid, and butyric acid by intestinal epithelial cells, exhibiting excellent ability to promote intestinal absorption of short-chain fatty acids. It can be used to prepare dairy products or beverages that promote the intestinal absorption of short-chain fatty acids.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention relates to the technical field of small molecule medicines, in particular to a medicine for improving chronic atrophic gastritis and application of the medicine. The invention aims to provide a compound, a pharmaceutical composition containing the compound and application of the compound, the 9, 13-substituted berberine derivative has a good improvement effect on CAG, and further research and observation of the compound on treatment of CAG gastric mucosa gland epithelial cell atrophy, gastric mucosa thinning, gastric mucosa epithelial cell atrophy, gastric mucosa hyperplasia, gastric mucosa epithelial cell atrophy and gastric mucosa hyperplasia. The 9, 13-substituted berberine derivative disclosed by the invention can be used for preventing and / or treating CAG (chorionic gonadotrophin) by virtue of the inhibition effects on infiltration adhesion of a large number of neutrophils and lymphocytes, inflammatory factors and the like.

The invention belongs to the technical field of marine microorganisms, and discloses an application of Propionibacterium fredenreici subsp. Schermani NHNK-616 in preparation of a product for improving macular retinae, the Propionibacterium fredenreici subsp. Schermani NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the Propionibacterium fredenreici subsp. Schermani NHNK-616 is CCTCC NO: M 20241429. The invention further discloses a preparation method of the Propionibacterium fredenreici subsp. Schermani NHNK-616. The inventor finds that the NHNK-616 has the functions of improving the oxidation resistance of the retina, increasing the retinal barrier, reducing retinal neovascularization, reducing retinal inflammation and the like, in addition, an NHNK-616 thallus biological membrane can improve the colonization capacity of nasal epithelial cells and intestinal epithelial cells, and the NHNK-616 can be used for preparing products for improving the retina macular.

The invention discloses a preparation method and application of a conditioned culture solution for improving the development rate of bovine in-vitro embryos. The preparation method comprises the following steps: culturing immortalized bovine endometrial epithelial cells by using a DMEM / F12 cell culture solution containing 10% FBS, collecting the cell culture solution in the culture process, and filtering to obtain an immortalized bovine endometrial epithelial cell conditional culture solution, namely the conditional culture solution capable of improving the development rate of the bovine in-vitro embryos. The prepared conditioned culture solution can simulate a liquid environment of an in-vivo environment, is used for culturing in-vitro embryos such as parthenogenetic activated embryos and in-vitro fertilized embryos, improves the cleavage rate and blastocyst rate of the in-vitro embryos and improves the development rate of the in-vitro embryos of cattle.

The invention discloses a lipid nanoparticle, a targeted lipid nanoparticle, and a preparation method and application thereof. The lipid nanoparticle has a core-shell structure, the core is formed by PLGA nanoparticles containing drug molecules, and the shell is formed by raw materials including phospholipid, cholesterol and a modification material; wherein the PLGA nanoparticles containing the drug molecules are formed by raw materials comprising PLGA and the drug molecules; the mass ratio of the PLGA to the phospholipid is (1-5): 1; the mass ratio of the phospholipid to the cholesterol is (3-10): 1, and the mass ratio of the phospholipid to the modification material is (3-10): 1; the drug molecules are selected from one or more of insoluble drugs, water-soluble drugs, genes and proteins; and the modification material is PEG-DSPE (Polyethylene Glycol Distearoyl The hardness of the lipid nanoparticles can be regulated and controlled, and cellular uptake can be improved by regulating and controlling the hardness; the targeted lipid nanoparticles can better improve cellular uptake, promote intestinal epithelial cell absorption and improve oral curative effect.

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.